A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Inclusion Criteria: * Written informed consent obtained prior to initiating any trial-specific procedures or assessments. * Male or female patients aged 18 years or over. * Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) at diagnosis and who have not received any treatment for their pancreatic cancer. * Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis. * Patients must have at least one measurable tumor lesion that can be imaged for assessments according to RECIST 1.1. * ECOG performance status of 0 or 1 at enrollment. * Must be willing to comply with the trial intervention, including prophylactic medications, and procedures. * Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment: Hematology: * Leukocytes ≥3.0x103 mcL * Absolute neutrophil count ≥1.5x10⁹/L * Hemoglobin ≥9 g/dL * Platelets ≥100x10⁹/L Coagulation: * Prothrombin time or international normalized ratio ≤1x upper limit of normal (ULN) * Activated partial thromboplastin time ≤1.2xULN Hepatic: * Total bilirubin ≤1.5xULN * ALT and AST ≤2.5xULN (\<5xULN is acceptable if liver metastases are present) Renal: * Serum creatinine ≤1.5xULN; or, * If serum creatinine \>1.5xULN, an estimated creatinine clearance \>50 mL/min using the Cockcroft and Gault formula Nutritional: • Serum Albumin ≥30 g/L \- Adequate left ventricular ejection fra…